Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Protara Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 76 | 1 | 81 | +6 |
| Shares | 29.7M | 1.57K | 26.2M | −3.50M (−11.8%) |
| Value | $90.1M | $4.92K | $114.0M | +$23.9M (+26.6%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Protara Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Driehaus Capital Management LLC | 444,444 | $1.93M | 0.01% |
| Assenagon Asset Management S.A. | 307,422 | $1.34M | 0.00% |
| Marex Group plc | 22,250 | $96.8K | 0.00% |
| Almanack Investment Partners, LLC. | 13,494 | $58.7K | 0.01% |
| Commonwealth Equity Services, LLC | 10,000 | $44.0K | 0.00% |
| Essential Partners LLC | 5,948 | $25.9K | 0.01% |
| Group One Trading, L.P. | 2,900 | $12.6K | 0.00% |
| Russell Investments Group, Ltd. | 2,676 | $11.6K | 0.00% |
| Advisory Services Network, LLC | 1,000 | $4.35K | 0.00% |
| The PNC Financial Services Group, Inc. | 117 | $509 | 0.00% |
| FMR LLC | 93 | $405 | 0.00% |
| Farther Finance Advisors, LLC | 55 | $239 | 0.00% |
| SRS Capital Advisors, Inc. | 48 | $209 | 0.00% |
| CWM, LLC | 42 | $0 | 0.00% |
Sold out (8)
Institutions that held Protara Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Ra Capital Management, L.P. | 1,039,295 | $3.15M |
| Opaleye Management Inc. | 855,000 | $2.59M |
| Woodline Partners LP | 851,674 | $2.58M |
| Adage Capital Partners GP, L.L.C. | 400,000 | $1.21M |
| Walleye Capital LLC | 161,091 | $488.1K |
| Deutsche Bank AG | 33,982 | $103.0K |
| Cubist Systematic Strategies, LLC | 19,679 | $59.6K |
| Raymond James Financial Inc | 271 | $821 |
Not filed for Q3 2025 yet (1)
Institutions that held Protara Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Semmax Financial Advisors Inc. | 1,572 | $4.92K |